Statins (HMG-CoA reductase inhibitors), cholesterol and stroke

被引：1

作者：

Marta-Moreno, J ^{[1
]}

Echeandia, C ^{[1
]}

Oliveros-Cid, A ^{[1
]}

Figuerola, A ^{[1
]}

Mola, S ^{[1
]}

机构：

[1] Hosp Miguel Servet, Serv Neurol, E-50009 Zaragoza, Spain

来源：

REVISTA DE NEUROLOGIA | 1998年 / 27卷 / 159期

关键词：

cerebral ischemia; cholesterol; HMG-CoA reductase; stroke;

D O I：

10.33588/rn.27159.98262

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The HMG-CoA reductase inhibitors (known as statins) have been shown to reduce morbi-mortality of vascular origin, including transitory ischemic accidents and cerebral infarcts, in a large group of patients. The implications, both clinical and of costs, oblige us to consider analysis of the existing evidence and the answers to a number of questions arising in a field which has not yet received much attention from neurologists.

引用

页码：827 / 830

页数：4

共 50 条

[31] HMG-CoA Reductase Inhibitors and Myotoxicity
Memduh Ucar
Tom Mjörndal
Rune Dahlqvist
Drug Safety, 2000, 22 : 441 - 457
[32] Rhabdomyolysis and HMG-CoA reductase inhibitors
Omar, MA
Wilson, JP
Cox, TS
ANNALS OF PHARMACOTHERAPY, 2001, 35 (09) : 1096 - 1107
[33] HMG-CoA reductase inhibitors and the kidney
Campese, V. M.
Park, J.
KIDNEY INTERNATIONAL, 2007, 71 (12) : 1215 - 1222
[34] HMG-CoA reductase inhibitors and the kidney
Campese, VA
Hadaya, B
Chiu, J
CURRENT HYPERTENSION REPORTS, 2005, 7 (05) : 337 - 342
[35] FIBRATES AND HMG-COA REDUCTASE INHIBITORS
HUFF, MW
CANADIAN MEDICAL ASSOCIATION JOURNAL, 1991, 145 (08) : 977 - 977
[36] HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein
Wang, EJ
Casciano, CN
Clement, RP
Johnson, WW
PHARMACEUTICAL RESEARCH, 2001, 18 (06) : 800 - 806
[37] MECHANISM FOR THE ACTION OF HMG-COA REDUCTASE INHIBITORS (CHOLESTEROL-SYNTHESIS INHIBITORS)
ENDO, A
NIPPON NOGEIKAGAKU KAISHI-JOURNAL OF THE JAPAN SOCIETY FOR BIOSCIENCE BIOTECHNOLOGY AND AGROCHEMISTRY, 1991, 65 (06): : 1019 - 1021
[38] HMG-CoA Reductase Inhibitors (Statins) Characterized as Direct Inhibitors of P-Glycoprotein
Er-jia Wang
Christopher N. Casciano
Robert P. Clement
William W. Johnson
Pharmaceutical Research, 2001, 18 : 800 - 806
[39] Advances in treatment of cholesterol abnormalities - The role of HMG-CoA reductase inhibitors
Rackley, CE
POSTGRADUATE MEDICINE, 1996, 100 (05) : 61 - +
[40] The rationale for using HMG-CoA reductase inhibitors ('statins') in peripheral arterial disease
Erez, G.
Leitersdorf, E.
EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 2007, 33 (02) : 192 - 201

← 1 2 3 4 5 →